Home › Funds › ADAR1 Capital Management, LLC › AMLX

ADAR1 Capital Management, LLC position in AMLX

AMYLYX PHARMACEUTICALS INC · Health Care

ADAR1 Capital Management, LLC reported holding 366,968 shares of AMLX (AMYLYX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$10.7M, representing 0.59% of its reported portfolio and ranking #46 among its reported holdings. ADAR1 Capital Management, LLC has disclosed AMLX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)366.97K sh
Reported value held$10.68M
Portfolio Weight0.59%
First reportedQ4 2023
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How ADAR1 Capital Management, LLC's AMLX position evolved

ADAR1 Capital Management, LLC first disclosed a stake in AMLX in Q4 2023 at 12,000 shares (US$177K). The position peaked in Q1 2026 at 1,000,604 shares, worth US$13.9M. Across 12 filings, ADAR1 Capital Management, LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 366,968 shares valued at US$10.7M — an increase of 326,868 shares quarter over quarter.. Notable position changes include a 165% increase in Q1 2024 (shares fell 33% over the following quarter), a 14616% increase in Q1 2025 (shares rose 81% over the following quarter), a 815% increase in Q3 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 12.00K $176.64K New
Q1 2024 31.80K $90.31K Add
Q2 2024 10.00K $19.00K Reduce
Q3 2024 10.00K $32.40K Hold
Q4 2024 10.00K $37.80K Hold
Q1 2025 1.47M $5.21M Add
Q2 2025 1.21M $7.72M Reduce
Q3 2025 866.20K $11.77M Reduce
Q4 2025 890.36K $10.76M Add
Q1 2026 1.00M $13.91M Add
Q2 2026 40.10K $720.20K Reduce
Q3 2026 366.97K $10.68M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AMLX and 13F data

AMLX (AMYLYX PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in AMLX — the largest reported positions include TCG Crossover Management, LLC (US$181.7M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$158.0M), PERCEPTIVE ADVISORS LLC (US$149.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AMLX

All AMLX fund holders →

FAQ

How long has ADAR1 Capital Management, LLC held AMLX?

ADAR1 Capital Management, LLC has disclosed AMLX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is ADAR1 Capital Management, LLC's current position in AMLX?

As of Q3 2026, ADAR1 Capital Management, LLC holds 366.97K shares of AMLX (AMYLYX PHARMACEUTICALS INC), valued at $10.68M, representing 0.59% of its reported portfolio and ranking #46.

Has ADAR1 Capital Management, LLC been buying or selling AMLX?

In the latest 13F filing (Q3 2026), ADAR1 Capital Management, LLC increased its position in AMLX. The position peaked in Q1 2026 at 1.00M shares.

Which other funds hold AMLX?

Other major institutional holders of AMLX include TCG Crossover Management, LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, PERCEPTIVE ADVISORS LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.